Проблемы сахароснижающей терапии у пациентов с сахарным диабетом при остром коронарном синдроме
https://doi.org/10.21518/2079-701X-2016-4-100-109
Аннотация
Об авторах
Л. А. Руяткина
Научно-исследовательский институт терапии и профилактической медицины
Россия
Россия
Д. С. Руяткин
Научно-исследовательский институт терапии и профилактической медицины
Россия
Россия
А. К. Овсянникова
Научно-исследовательский институт терапии и профилактической медицины
Россия
Россия
Список литературы
1. Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. European Heart Journal, 2012, 14(Suppl. B): 4-13.
2. Какорин С.В., Круглый, Л.Б., Мкртумян А.М. Клинико-морфологические особенности, прогноз и тактика лечения острого коронарного синдрома у больных сахарным диабетом 2 типа. Сахарный диабет, 2013, 2: 36-42.
3. Сыркин А.Л., Новикова Н.А., Терехин С.А. Острый коронарный синдром. М.: МИА, 2010: 458.
4. Шахнович Р.М. Острый коронарный синдром с подъемом сегмента ST. М.: ГЭОТАР-Медиа, 2010:17-18.
5. Ferrannini E, DeFronzo RA. Impact of Glucose-lowering Drugs on Cardiovascular Disease in Type 2 Diabetes. Eur Heart J., 2015, Sep 7, 36: 2288-2296. doi: 10.1093/eurheartj/ehv239.
6. Эрлих А.Д., Грацианский Н.А., участники регистра РЕКОРД. Острый коронарный синдром у больных сахарным диабетом. Данные регистра РЕКОРД. Кардиология, 2011, 11: 16-21.
7. Какорин С.В., Карамышев Д.В., Мкртумян А.М., Нефедова Г.А. Клинико-морфо-логические особенности острого инфаркта миокарда у больных сахарным диабетом 2 типа. Сердце: журнал для практикующих врачей, 2014, 13, 6(80): 347-353.
8. Аблина К.Н., Какорин С.В. Острый коронарный синдром и хроническая сердечная недостаточность у больных сахарным диабетом 2 типа, осложненным кардионейропати-ей. Вестник Национального медико-хирургического Центра им. Н.И. Пирогова, 2015, 10(1): 94-97.
9. Какорин С.В., Шашкова Л.С., Мкртумян А.М. Острый коронарный синдром у пациентов с нарушениями углеводного обмена. Сердце: журнал для практикующих врачей, 2012, 11(1): 8-12.
10. Каретникова В.Н., Барбараш О.Л., Квиткова Л.В., Груздева О.В., Еленская Т.С., Благовещенская О.П. и др. Раннее выявление нарушений углеводного метаболизма - важный маркер отдаленного прогноза при инфаркте миокарда. Патология кровообращения и кардиохирургия, 2010, 2: 33-37.
11. Квиткова Л.В., Еленская Т.С., Благовещенская О.П., Зинчук С.Ф., Зинчук В.Г., Барбараш О.Л. Влияние инсулинорезистентности и нарушений углеводного обмена на течение острого периода инфаркта миокарда. Проблемы эндокринологии, 2011, 2: 9-13.
12. Bartnik М, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe (The Euro Heart Survey on diabetes and the heart). European Heart Journal, 2004, 25: 1880-1890.
13. Norhamar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes melli-tus: a prospective study. Lancet, 2002, 359: 2140-2144.
14. Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R et al. The association of fasting glucose levels with congestive heart failure in diabetic adults £65 years. The Cardiovascular Health Study. J Am Coll Cardiol, 2004, 43: 2236-2241.
15. Ryden L, Grant PJ, Anker SD, Berne C. Cosentino F., Danchin N. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34: 30353087. doi:10.1093/eurheartj/eht108.
16. Стронгин Л.Г., Беляева Н.Г., Панова Е.И. Значение гликемического контроля в остром периоде инфаркта миокарда у больных сахарным диабетом 2 типа. Сахарный диабет, 2008, 1: 15-18.
17. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J, 2006, 27: 1289-1297.
18. Center for Drug Evaluation and Research. Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, 2008 //http//www.fda.gov/down-loads/drugs/guidancecomplianceregulatoryin-formation/guidances/ucm071627.pdf.
19. Malmberg K, Norhammar A, Wedel H, Ryd L. Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction: Long-Term Results From the Diabetes and Insulin- Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation, 1999, 99: 2626-2632.
20. Malmberg K, Ryd L, Wedel H, Birkeland K, Bootsma A, Dickstein K. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J, 2005, 26: 650-661.
21. Федотова А.И., Катков В.А., Максимов И.В., Марков В.А. Опыт применения протокола инфузионной инсулинотерапии в остром периоде инфаркта миокарда при сахарном диабете. Сибирский медицинский журнал, 2011, 4(2): 132-135.
22. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T et al. Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation, 2008, 117: 1610-1619.
23. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care, 2013, 36(1): 11-66., doi: 10.2337/dc13-S011.
24. Дедов И.И., Александров А.А. Проблемы острого инфаркта миокарда у больных сахарным диабетом: эхо Мюнхена. Сахарный диабет, 2008, 1: 4-8.
25. The NICE-SUGAR Study Investigators. Intensive versus Conventional Glucose Control in Critically Ill Patients. N Engl J Med, 2009, 360: 1283-97. doi: 10.1056/ NEJMoa0810625.
26. Руяткина Л.А., Руяткин Д.С., Березовская Г.А. Гипогликемии в патогенезе сердечно-сосудистого риска. Фарматека, 2013, 6: 15-18.
27. Полторак В.В. Феномен ишемического пре-кондиционирования: эффект глюкозного дисбаланса и антидиабетической терапии. Международный эндокринологический журнал, 2013, 2(50): 68-74.
28. Ritsinger V, SaLeh N, Lagerqvist B, Norhammar A. High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes MeLLitus. Results From the Swedish Coronary Angiography and Angioplasty Registry. Circulation: Cardiovascular Interventions, 2015, 8: e002328. doi:10.1161/ CIRCINTER VENTIONS. 114.002328.
29. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP et aL. BasaL insulin and cardiovascular and other outcomes in dysgLy-cemia. N Engl J Med, 2012, 4(367): 319-328. doi: 10.1056/NEJMoa1203858.
30. Gore O, McGuire D. The 10-year post-trial foLLow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascuLar observations in context. Diab. Vasc. Dis. Res, 2009, 6: 53.
31. Александров А.А. «Флорентийская перспектива»: механизмы формирования. Эффективная фармакотерапия, 2012, 49: 40-45.
32. Shi NO, Ye B, MakieLski JC. Function and distribution of the SUR isoforms and spLice variants. J. Mol. Cell. Cardiol, 2005, 39(1): 51-60.
33. ArdehaLi H, O'Rourke B. MitochondriaL K (AT P) channeLs in ceLL survivaL and death. J. Mol. Cell. Cardiol, 2005, 39(1): 7-16.
34. Панькив В.И. Место глибенкламида в диалектике современной сахароснижающей терапии с позиций безопасности и кардио-протекции. Международный эндокринологический журнал, 2013, 2(50): 55-61.
35. Недосугова Л.В. Препараты сульфонилмоче-вины и риск сердечно-сосудистых осложнений - "много шума из ничего"? Фарматека, 2010, 3: 22-31.
36. Zoungas S, PateL A, ChaLmers J, de GaLan BE, Li O, BiLLot L et aL. Severe HypogLycemia and Risks of VascuLar Events and Death. N Engl J Med, 2010, 363: 1410-1418. doi: 10.1056/ NEJMoa1003795.
37. Руяткина Л.А., Сорокин М.Ю. Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность. Сахарный диабет, 2012, 2: 89-97.
38. Fisman EZ, Tenenbaum A. Antidiabetic Treatment With GLiptins: Focus on CardiovascuLar Effects and Outcomes. Cardiovasc Diabetol, 2015, 14: 129.
39. Inzucchi SE, BergenstaL RM, Buse JB, Diamant M, Ferrannini E, Nauck M et aL. Management of hypergLycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38(1): 140-149.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive bLood gLucose controL with suLphonyLureas or insuLin compared with conventionaL treatment and risk of compLications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352: 837853.
41. Effect of intensive bLood-gLucose controL with metformin on compLications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352: 854-865.
42. BaiLey CJ, CampbeLL IW, Chan JCN, Davidson JA, HowLett HCS, Ritz P. Metformin the goLd standard - a scientific handbook, 2007, PubLished by John WiLey & Sons Ltd Chichester, UK: 288.
43. ALessi MC, Juhan-Vague I. PAI-1 and the metaboLic syndrome: the Links, causes and consequences. Arterioscler Thromb. Vasc. Biol, 2006, 26: 2200-2207.
44. SeLvin E, BoLen S, Hsin-Chieh Y, WiLey C, WiLson L. A Systematic Review CardiovascuLar Outcomes in TriaLs of OraL Diabetes Medications. Arch Intern Med, 2008, 168(19): 2070-2080.
45. Isoda K, Young JL, ZirLik A, MacFarLane LA, Tsuboi N, Gerdes N et aL. Metformin inhibits proinfLammatory responses and nucLear factor kappaB in human vascuLar waLL ceLLs. Arterioscler. Thromb. Vasc. Biol, 2006, 26: 611-7.
46. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG. Effect of metformin on Left ventricuLar function after acute myocardiaL infarction in patients without diabetes: the GIPS-III randomized cLinicaL triaL. JAMA, 2014, 16, 311(15): 1526-35. doi: 10.1001/jama.2014.3315.
47. Bonora E. PostprandiaL peaks as a risk factor for cardiovascuLar disease: epidemioLogicaL perspectives. J Clin Pract Suppl, 2002, 129: 5-11.
48. CerieLLo A, Davidson J, HanefeLd M, Leiter L, Monnier L, Owens D et aL. PostprandiaL hyper-gLycaemia and cardiovascuLar compLications of diabetes: an update. Nutr Metab Cardiovasc Dis. 2006, 16(7): 453-456.
49. Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений. Сахарный диабет, 2014, 2: 76-82.
50. Su G, Mi S, Li Z, Tao H, Yang H, Zheng H. Prognostic vaLue of earLy in-hospitaL gLycemic excursion in eLderLy patients with acute myo-cardiaL infarction. Cardiovasc Diabetol, 2013, 12(1): 33. doi: http//dx.doi.org/10.1186/1475-2840-12-33.
51. Deacon CF, Mannucci E, Ahren B. GLycaemic efficacy of gLucagon-Like peptide-1 receptor agonists and dipeptidyL peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta anaLysis. Diabetes Obes Metab, 2012, 14(8): 762-767.
52. Nauck MA, Meininger G, Sheng D, TerraneLLa L, Stein PP, SitagLiptin Study 024 Group. Efficacy and safety of the dipeptidyL pepti-dase-4-inhibitor, sitagLiptin, compared with suLfonyLurea, gLipizide in patients with type 2 diabetes inadequateLy controLLed on met-formin aLone: a randomized, doobLe-bLind, non-inferiority triaL. Diabetes Obes Metab, 2007, 9: 194-205.
53. Руяткина Л.А., Сорокин М.Ю. Выбор глиптинов в разных клинических ситуациях -комментарии к портретам пациентов. Фарматека, 2012, 20: 89-95.
54. Hage C, Brismar K, Efendic S, Lundman P, Ryden L, MeLLbin L. SitagLiptin improves beta-ceLL function in patients with acute coronary syndromes and newLy diagnosed gLucose abnormaLities-the BEGAMI study. J. Intern Med, 2013, 273(4): 410-421.
55. White WB, Cannon CP, HeLLer SR, Nissen SE, BergenstaL RM, Bakris GL et aL. ALogLiptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med., 2013 Oct 3, 369(14): 1327-35. doi: 10.1056/ NEJMoa1305889.
56. Scirica BM, Bhatt DL, BraunwaLd E, Steg PG, Davidson J, Hirshberg B et aL. SaxagLiptin and cardiovascuLar outcomes in patients with type 2 diabetes meLLitus. N Engl J Med. 2013 Oct 3, 369(14): 1317-26. doi: 10.1056/ NEJMoa1307684.
57. Green JB, BetheL MA, Armstrong PW, Buse JB, EngeL SS, Garg J et aL. Effect of SitagLiptin on CardiovascuLar Outcomes in Type 2 Diabetes. N Engl J Med., 2015 JuL 16, 373(3): 232-42. doi: 10.1056/NEJMoa1501352.
58. BentLey-Lewis R, AguiLar D, RiddLe MC, CLaggett B, Diaz R, Dickstein K et aL. RationaLe, design, and baseLine characteristics in EvaLuation of LIXisenatide in Acute Coronary Syndrome, a Long-term cardiovascuLar end point triaL of Lixisenatide versus pLacebo. Am Heart J., 2015 May, 169(5): 631-638.e7. doi: 10.1016/j.ahj.2015.02.002.
59. Huo X, Gao L, Guo L, Xu W, Wang W, Zhi H et aL. Risk of non-fataL cardiovascuLar diseases in earLy-onset versus Late-onset type 2 diabetes in China: a cross-sectionaL study. The Lancet. Diabetes & endocrinology, 2015, 4(2): 115-124.
60. Soon H Song. EarLy-onset type 2 diabetes: high Lifetime risk for cardiovascuLar disease. The Lancet Diabetes & Endocrinology, 2015, 4(2): 87-88.
61. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S et aL. Excess MortaLity among Persons with Type 2 Diabetes. N Engl J Med, 2015, 373: 1720-1732.
62. Lee C, Joseph L, CoLosimo A, Dasgupta K. Review MortaLity in diabetes compared with previous cardiovascuLar disease: A gender-specific meta-anaLysis. Diabetes & Metabolism, 2012, 38: 420-427.
63. Hu G, JousiLahti P, Oiao O, PeLtonen M, Katoh S, TuomiLehto J. The Gender-Specific Impact of Diabetes and MyocardiaL Infarction at BaseLine and During FoLLow-Up on MortaLity From ALL Causes and Coronary Heart Disease. Journal of the American College of Cardiology, 2005, 45(9): 1413-1418.
64. SzaLat Auryan S, Itamar R. Gender-specific care of diabetes meLLitus: ParticuLar considerations in the management of diabetic women. Diabetes, Obesity and Metabolism, 2008, 10: 1135-1156.
65. Comitato R, Saba A, Turrini A, Arganini C, VirgiLi F. Sex hormones and macronutrient metaboLism. Crit Rev Food Sci Nutr., 2015, 55(2): 227-41.
66. VarLamov O, Bethea CL, Roberts CT. Sex-specific differences in Lipid and gLucose metaboLism. Front Endocrinol (Lausanne), 2015, 19(5): 241.
67. Chatterjee S, Peters SAE, Woodward M. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A PooLed AnaLysis of 2.3 MiLLion PeopLe Comprising More Than 100,000 Cases of Dementia. Diabetes Care, 2015. doi:10.2337/dc15-1588.
68. Arnetz L, Ekberg NR, ALvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes., 2014, 16(7): 409-420.
69. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A et aL. GLP-1 Response to OraL GLucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and InfLuenced by Sex: The ADDITION-PRO Study. Diabetes, 2015, 64(7): 2513-2525.
70. Asanuma H, Kitakaze M. GLycemic VariabiLity Predicts Rapid Progression of Non-CuLprit Lesions in Patients With Acute Coronary Syndrome. Circ J., 2015, 79(10): 2114-5. doi: 10.1253/circj.CJ-15-0919.
71. White WB, Kupfer Stuart et aL. CardiovascuLar mortaLity in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE triaL. J Am Coll Cardiol., 2014, 63(12_S): A116.
72. Kakorin S.V., Krugliy L.B., Mkrtumian A.M. Clinico-morphological features, prognosis and treatment of acute coronary syndrome in patients with type 2 diabetes. Sakharniy Diabet, 2013, 2: 36-42.
73. Syrkin A.L., Novikova N.A., Terekhin S.A. Acute coronary syndrome. М.: MIA, 2010: 458.
74. Shakhnovich R.M. Acute coronary syndrome with ST segment elevation. М.: GEOTARMedia, 2010: 17-18.
75. Ferrannini E, DeFronzo RA. Impact of Glucose-lowering Drugs on Cardiovascular Disease in Type 2 Diabetes. Eur Heart J., 2015, Sep 7, 36: 2288-2296. doi: 10.1093/eurheartj/ehv239.
76. Erlich A.D., Gratsiansky N.A., participants of the RECORD registry. Acute coronary syndrome in patients with diabetes mellitus. Data from the RECORD registry. Kardiologiya, 2011, 11: 16-21.
77. Kakorin S.V., Karamyshev D.V., Mkrtumian A.M., Nefedova G.A. Clinical and morphological features of acute myocardial infarction in patients with type 2 diabetes. Serdtse: Zhurnal dlya Praktikuyuschikh Vrachey 2014, 13, 6 (80): 347-353.
78. Ablina K.N., Kakorin S.V. Acute coronary syndrome and chronic heart failure in patients with type 2 diabetes mellitus complicated by cardioneuropathy. Vestnik Natsionalnogo MedikoKhirurgicheskogo Tsentra im. N.I. Pirogova, 2015, 10(1): 94-97.
79. Kakorin S.V., Shashkova L.S., Mkrtumian A.M. Acute coronary syndrome in patients with impaired carbohydrate metabolism. Serdtse: Zhurnal dlya Praktikuyuschikh Vrachey 2012, 11 (1): 8-12.
80. Karetnikova V.N., Barbarash O.L., Kvitkova L.V., Gruzdeva O.V., Elenskaya T.S., Blagoveschenskaya O.P. et al. Early detection of carbohydrate metabolism disorders is an important marker of long-term prognosis in myocardial infarction. Patologiya Krovoobrascheniya i Kardiokhirurgiya, 2010, 2: 33-37.
81. Kvitkova L.V., Elenskaya T.S., Blagoveschenskaya O.P., Zinchuk S.F., Zinchuk V.G., Barbarash O.L. The effect of insulin resistance and disorders of carbohydrate metabolism on the course of acute myocardial infarction. Problemy Endokrinologii, 2011, 2: 9-13
82. Strongin L.G., Belyaeva N.G., Panova E.I. The value of glycemic control during the acute phase of myocardial infarction in patients with type 2 diabetes. Sakharniy Diabet, 2008, 1: 15-18.
83. Fedotova A.I., Katkov V.A., Maksimov I.V., Markov V.A. Experience with the insulin infusion protocol in the acute phase of myocardial infarction in patients with diabetes mellitus. Sibirskiy Meditsinskiy Zhurnal, 2011, 4(2): 132-135.
84. Dedov I.I., Aleksandrov A.A. Problems of acute myocardial infarction in patients with diabetes: echo of Munich. Sakharniy Diabet, 2008, 1: 4-8.
85. Ruyatkina L.A., Ruyatkin D.S., Berezovskaya G.A. Hypoglycemia in the pathogenesis of cardiovascular risk. Farmateka, 2013, 6: 15-18.
86. Poltorak V.V. The phenomenon of ischemic preconditioning: the effecs of glucose imbalance and antidiabetic therapy. Mezhdunarodniy Endokrinologicheskiy Zhurnal, 2013, 2(50): 68-74
87. Aleksandrov A.A. "Florentine perspective": mechanisms of formation. Effektivnaya Farmakoterapiya, 2012, 49: 40-45.
88. Pankiv V.I. The place of glibenclamide in the dialectics of the present-day antidiabetic therapy from the standpoint of safety and cardioprotection. Mezhdunarodniy Endokrinologicheskiy Zhurnal, 2013, 2(50): 55-61.
89. Nedosugova L.V. Sulfonylurea drugs and the risk of cardiovascular complications - "much ado about nothing"? Farmateka, 2010, 3: 22-31.
90. Ruyatkina L.A., Sorokin M.Y. Glimepiride in the present-day hypoglycemic therapy: safety and effectiveness. Sakharniy Diabet, 2012, 2: 89-97
91. Aleksandrov A.A. "Florentine perspective": mechanisms of formation. Effektivnaya Farmakoterapiya, 2012, 49: 40-45.
92. Pankiv V.I. The place of glibenclamide in the dialectics of the present-day antidiabetic therapy from the standpoint of safety and cardioprotection. Mezhdunarodniy Endokrinologicheskiy Zhurnal, 2013, 2(50): 55-61.
93. Nedosugova L.V. Sulfonylurea drugs and the risk of cardiovascular complications - "much ado about nothing"? Farmateka, 2010, 3: 22-31.
94. Ruyatkina L.A., Sorokin M.Y. Glimepiride in the present-day hypoglycemic therapy: safety and effectiveness. Sakharniy Diabet, 2012, 2: 89-97
95. Ruyatkina L.A., Sorokin M.Y. Selecting gliptins in different clinical situations - comments to patients' portraits. Farmateka, 2012, 20: 89-95.
Рецензия
Для цитирования:
Руяткина Л.А., Руяткин Д.С., Овсянникова А.К. Проблемы сахароснижающей терапии у пациентов с сахарным диабетом при остром коронарном синдроме. Медицинский Совет. 2016;(4):100-109. https://doi.org/10.21518/2079-701X-2016-4-100-109
For citation:
Ruyatkina L.A., Ruyatkin D.S., Ovsyannikova A.K. Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome. Meditsinskiy sovet = Medical Council. 2016;(4):100-109. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-100-109
Просмотров: 859
Послать статью по эл. почте 